Spot Trading’s Arbutus Biopharma ABUS Stock Holding History

Spot Trading’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1	Closed	–	–	3259
2016 Q1	$0	Buy	+1	New	+$4	﹤0.01%	3368
2014 Q4	–	Sell	-742	Closed	-$16K	–	3958
2014 Q3	$16K	Buy	+742	New	+$12.1K	﹤0.01%	3986

Other funds holding ABUS

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Suffolk Capital Management New York $521M AUM 9.79% 1-Year Est. Return

Spot Trading's ABUS Position: Q2 2016 in Review

Spot Trading sold out of Arbutus Biopharma (ABUS) in Q2 2016, closing a stake of 1 share.

Spot Trading first reported a position in ABUS in Q3 2014 and held it in 2 quarters. The position peaked at $16K in Q3 2014. 51 funds tracked by Wall St. Rank hold ABUS as of Q2 2016.

Spot Trading reported no remaining Arbutus Biopharma position as of Q2 2016 after selling out during the quarter.
Spot Trading sold 1 Arbutus Biopharma share in Q2 2016.
Spot Trading first reported a position in Arbutus Biopharma in Q3 2014 and held it in 2 quarters.
Spot Trading's Arbutus Biopharma position peaked at $16K in Q3 2014.
51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2016.

Based on Spot Trading's 13F filing for Q2 2016, filed 2 Aug 2016.